P.S.K Biosciences to Present at the CBI2026 CGT Therapy Innovation Conference

The CBI2026 Biopharma Innovation Expo will be held at Hall B of the Suzhou International Expo Center from September 4 to 5, 2026. Dr. Tinghe Wu, Founder and CEO of P.S.K Biosciences, has been invited to attend the CBI2026 CGT Therapy Innovation Conference and will serve as a co-planner of the Exosome Industry Diversification Forum on the afternoon of September 4.

During the conference, Dr. Wu will deliver a presentation titled “Competitive Landscape and Future Outlook of Brain-Penetrant Nucleic Acid Delivery Technology Platforms.” The presentation will focus on key challenges in CNS nucleic acid delivery, the evolving competitive landscape, and future development trends in the field.

P.S.K Biosciences is focused on the development of an engineered exosome-based RNA delivery platform designed to overcome key delivery barriers in the central nervous system and extrahepatic tissues. The Company has made encouraging progress in nucleic acid loading efficiency, target gene knockdown across multiple brain regions, repeat dosing feasibility, and cross-target reproducibility. In parallel, P.S.K Biosciences continues to advance its CMC and quality control framework to support long-term therapeutic applications and industrial-scale development of engineered exosome delivery technologies.

The Company’s participation and presentation at CBI2026 reflect its continued commitment to engineered exosome delivery and brain-penetrant nucleic acid therapeutics. Moving forward, P.S.K Biosciences will continue to advance its engineered exosome RNA delivery platform and accelerate the translational application of exosome technologies in CNS diseases and other areas with significant unmet medical needs.

Forum InformationForum: CBI2026 CGT Therapy Innovation ConferenceDate: September 4–5, 2026Venue: Hall B101, Suzhou International Expo Center

P.S.K Biosciences
Corporate Communications
July 8, 2026